David Moore

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

The Lancet · 2017 · 530 citations

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

Journal of Clinical Oncology · 2004 · First of 11 authors · Corresponding · 469 citations